Cor­ner Ther­a­peu­tics to hy­per­ac­ti­vate ‘the brains of the im­mune sys­tem’ with $54M launch

Cor­ner Ther­a­peu­tics’ $54 mil­lion Se­ries A will be used to bring new im­munother­a­pies for can­cer and in­fec­tious dis­eases in­to the clin­ic, the com­pa­ny said Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.